Assertio Holdings, Inc. (ASRT) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Earnings Reports
-
Assertio (ASRT) Q2 2025: Rolvidon Demand Grows 20%, Driving Strategic Transformation
June 16, 2026
-
Assertio Holdings (ASRT) Q4 2025: Rolvidon Demand Grows 32% as Oncology Focus Drives 2026 Strategy
June 15, 2026
-
Assertio (ASRT) Q4 2025: Rolvidon Drives 32% Demand Growth as Oncology Focus Deepens
June 15, 2026